Literature DB >> 1316387

Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo.

N Mozzanica1, M L Villa, S Foppa, G Vignati, A Cattaneo, R Diotti, A F Finzi.   

Abstract

BACKGROUND: The immune system is important in the pathogenesis of vitiligo, and emotional stress has precipitated vitiligo in some patients. Opioid peptides, beta-endorphin, met-enkephalin, and alpha-melanocyte-stimulating hormone (MSH) act as immunomodulators, and their secretion increases during periods of stress.
OBJECTIVE: To see whether these three neuropeptides might be related to vitiligo itself or to some alterations of the immune system in patients with vitiligo, we compared circadian variations in their plasma concentrations and natural killer cell activity of peripheral blood lymphocytes in 14 patients with vitiligo with those of 12 healthy subjects.
METHODS: Plasma concentrations of neurohormones were evaluated by radioimmunoassay (immunoradiometric assay for beta-endorphin). Natural killer cell activity (NKCA) was assayed against K562 cells by 51Cr release technique. Data were compared by the Student t test and analyzed by cosinor analysis.
RESULTS: The NKCA in vitiligo patients was higher than in controls but had similar circadian rhythm. alpha-MSH had no circadian rhythm in controls or in patients; plasma alpha-MSH levels were the same. Daily met-enkephalin and beta-endorphin oscillations in patients were no longer circadian. beta-Endorphin plasma levels in stable vitiligo were higher than in controls. There were no differences between patients with active vitiligo and normal subjects. Met-enkephalin plasma levels were generally higher in vitiligo patients, especially in the one with active vitiligo, than in controls.
CONCLUSION: In vitiligo there are aberrations in neuropeptide, beta-endorphin, and met-enkephalin secretion. The plasma met-enkephalin level is positively correlated with the aggressiveness of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316387     DOI: 10.1016/0190-9622(92)70094-v

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  New treatment modalities for vitiligo: focus on topical immunomodulators.

Authors:  Kresimir Kostovic; Aida Pasic
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Circadian rhythms and pain.

Authors:  Jacob R Bumgarner; William H Walker; Randy J Nelson
Journal:  Neurosci Biobehav Rev       Date:  2021-08-08       Impact factor: 9.052

3.  The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study.

Authors:  P Y Liu; L Bondesson; W Löntz; O Johansson
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

4.  Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio.

Authors:  Robert Pichler; Konstantin Sfetsos; Birgit Badics; Sabrina Gutenbrunner; Jörg Berg; Josef Auböck
Journal:  Wien Med Wochenschr       Date:  2009

Review 5.  Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective.

Authors:  Katia Boniface; Thierry Passeron; Julien Seneschal; Meri K Tulic
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

6.  Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin.

Authors:  Richard Yu; Raewyn Broady; Yuanshen Huang; Yang Wang; Jie Yu; Min Gao; Megan Levings; Shencai Wei; Shengquan Zhang; Aie Xu; Mingwan Su; Jan Dutz; Xuejun Zhang; Youwen Zhou
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.